Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNYSE:ATNMNASDAQ:DSGNNASDAQ:ENGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$10.33+2.3%$8.53$5.51▼$11.73$201.77MN/A48,059 shs46,719 shsATNMActinium Pharmaceuticals$1.64-3.5%$1.45$1.03▼$8.68$51.16M-0.24500,549 shs141,738 shsDSGNDesign Therapeutics$3.81-1.6%$3.77$2.60▼$7.77$216.29M1.77186,686 shs184,751 shsENGNenGene$4.24-1.2%$4.07$2.65▼$13.00$216.15M-0.36132,554 shs45,475 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+2.28%-2.09%+14.78%+34.33%+1,032,999,900.00%ATNMActinium Pharmaceuticals-3.53%-1.80%+26.15%+40.17%-83.27%DSGNDesign Therapeutics-1.55%+8.55%-6.39%-22.40%-8.41%ENGNenGene-1.17%+22.90%+6.27%-32.08%-67.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AATNMActinium Pharmaceuticals1.1953 of 5 stars3.40.00.00.01.10.00.6DSGNDesign Therapeutics0.5572 of 5 stars1.00.00.00.03.22.50.6ENGNenGene2.5698 of 5 stars3.53.00.00.01.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.5098.45% UpsideATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00143.90% UpsideDSGNDesign Therapeutics 2.00Hold$4.004.99% UpsideENGNenGene 3.00Buy$23.29449.19% UpsideCurrent Analyst Ratings BreakdownLatest ATNM, ACTU, DSGN, and ENGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/29/2025ENGNenGeneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/22/2025ACTUActuate TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/1/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/25/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/18/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/17/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.003/11/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/11/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.003/11/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AATNMActinium Pharmaceuticals$81K631.62N/AN/A$1.31 per share1.25DSGNDesign TherapeuticsN/AN/AN/AN/A$4.96 per shareN/AENGNenGeneN/AN/AN/AN/A$6.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/AATNMActinium Pharmaceuticals-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/ADSGNDesign Therapeutics-$66.86M-$0.99N/AN/AN/AN/A-18.01%-17.38%8/4/2025 (Estimated)ENGNenGene-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%6/10/2025 (Estimated)Latest ATNM, ACTU, DSGN, and ENGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2025Q2 2025ENGNenGene-$0.4768N/AN/AN/AN/AN/A5/15/2025Q1 2025ACTUActuate Therapeutics-$0.26-$0.32-$0.06-$0.32N/AN/A5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A3/10/2025Q4 2024DSGNDesign Therapeutics-$0.28-$0.24+$0.04-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AENGNenGene$1.5837.29%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.681.68ATNMActinium PharmaceuticalsN/A10.2510.25DSGNDesign TherapeuticsN/A34.6134.61ENGNenGene0.0816.8716.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AATNMActinium Pharmaceuticals27.50%DSGNDesign Therapeutics56.64%ENGNenGene64.16%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%ATNMActinium Pharmaceuticals6.00%DSGNDesign Therapeutics31.20%ENGNenGene10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.53 millionN/AN/AATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableDSGNDesign Therapeutics4056.77 million38.96 millionOptionableENGNenGene3150.98 million38.16 millionN/AATNM, ACTU, DSGN, and ENGN HeadlinesRecent News About These CompaniesSpaceX blames Starship Flight 8 mishap on engine hardware failureMay 23 at 8:46 PM | spacenews.comHouston-based Venus Aerospace achieves ‘world first' during rocket engine test for high-speed planeMay 23 at 3:45 PM | msn.comDelta flight that had to be evacuated amid thick smoke after emergency landing had ‘no oil visible’ in one engine, report showsMay 22 at 2:01 PM | msn.comVR Adviser LLC Has $33.56 Million Holdings in enGene Holdings Inc. (NASDAQ:ENGN)May 22 at 6:53 AM | marketbeat.comHow Much Does it Cost to Replace an Engine?May 21 at 6:45 PM | msn.comCan You Top Up Engine Oil Instead Of Changing It?May 21 at 6:45 PM | msn.comNo oil found in engine after Delta Air Lines flight filled with smoke, NTSB report findsMay 21 at 6:45 PM | msn.comBirds were sucked into both engines of FedEx cargo plane that made a fiery landing, NTSB preliminary report findsMay 21 at 6:45 PM | msn.comVestal Point Capital LP Buys Shares of 370,000 enGene Holdings Inc. (NASDAQ:ENGN)May 21 at 8:14 AM | marketbeat.comPoint72 Asset Management L.P. Boosts Holdings in enGene Holdings Inc. (NASDAQ:ENGN)May 21 at 5:27 AM | marketbeat.comSphera Funds Management LTD. Invests $3.72 Million in enGene Holdings Inc. (NASDAQ:ENGN)May 18, 2025 | marketbeat.comAnalyzing Tourmaline Bio (NASDAQ:TRML) & enGene (NASDAQ:ENGN)May 16, 2025 | americanbankingnews.comOrbimed Advisors LLC Invests $6.12 Million in enGene Holdings Inc. (NASDAQ:ENGN)May 15, 2025 | marketbeat.comenGene Holdings Inc. (NASDAQ:ENGN) Position Decreased by Omega Fund Management LLCMay 15, 2025 | marketbeat.comFcpm Iii Services B.V. Purchases 954,610 Shares of enGene Holdings Inc. (NASDAQ:ENGN)May 11, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Decreases Stake in enGene Holdings Inc. (NASDAQ:ENGN)May 11, 2025 | marketbeat.comGM 6.2L V8 L87 Engines That Need New Oil Viscosity, And Those That Don’tMay 10, 2025 | gmauthority.comUS Pratt engine strikers press for jobs commitment, union saysMay 9, 2025 | msn.comDeep Track Capital LP Acquires 1,949,942 Shares of enGene Holdings Inc. (NASDAQ:ENGN)May 9, 2025 | marketbeat.comAlphabet shares sink 8% after Apple's Cue says AI will replace search enginesMay 7, 2025 | nbcwashington.comCommon Problems With The BMW B48 Engine (According To Owners)May 7, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongNVIDIA’s NVLink Fusion Ups the Ante for AI InfrastructureBy Thomas Hughes | May 19, 2025View NVIDIA’s NVLink Fusion Ups the Ante for AI InfrastructureRockwell Automation: Tailwinds From Onshoring U.S. ProductionBy Thomas Hughes | May 8, 2025View Rockwell Automation: Tailwinds From Onshoring U.S. ProductionCan Shopify Stock Make a Comeback After an Earnings Sell-Off?By Gabriel Osorio-Mazilli | May 12, 2025View Can Shopify Stock Make a Comeback After an Earnings Sell-Off?ATNM, ACTU, DSGN, and ENGN Company DescriptionsActuate Therapeutics NASDAQ:ACTU$10.31 +0.21 (+2.12%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Actinium Pharmaceuticals NYSE:ATNM$1.64 -0.06 (-3.53%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.63 -0.01 (-0.37%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Design Therapeutics NASDAQ:DSGN$3.81 -0.06 (-1.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.81 0.00 (0.00%) As of 05/23/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.enGene NASDAQ:ENGN$4.24 -0.05 (-1.17%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.25 +0.01 (+0.24%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
